Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • View Item
  • Home
  • ICR Divisions
  • Cancer Biology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Thumbnail
Publication Date
2012-12
ICR Author
Kyula, Joan
Harrington, Kevin
Author
Kyula, JN
Roulstone, V
Karapanagiotou, EM
Melcher, AA
Harrington, KJ
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Introduction</h4>Locally advanced head and neck cancer carries a poor prognosis, even with standard combination (surgery, radiotherapy, chemotherapy) treatment regimens. There is a pressing need for novel therapies with activity against this tumour type. Oncolytic reovirus type 3 (Dearing) is preferentially cytotoxic in tumour cells with an activated Ras signalling pathway and represents a promising novel therapy with relevance in head and neck cancer.<h4>Areas covered</h4>In this review, we discuss the pre-clinical and clinical data that have underpinned the translational development of oncolytic reovirus thus far. In particular, we describe the iterative nature of the research programme through initial studies testing single-agent reovirus therapy and on to subsequent work in which reovirus has been combined with either radiotherapy or cytotoxic chemotherapy. We will trace the process by which oncolytic reovirus has reached Phase III evaluation in combination with carboplatin/paclitaxel in patients with platin-refractory, relapsed/metastatic head and neck cancer.<h4>Expert opinion</h4>Reovirus is a self-amplifying, cancer-selective agent that offers huge potential advantages over standard chemotherapy, targeted small molecules or monoclonal antibodies. However, it is most likely that reovirus will show efficacy and be approved in combination with standard modalities (cytotoxic chemotherapy or radiotherapy) or other targeted agents, especially those that modulate signal transduction pathways. The next 5 years are critical for the development of oncolytic reovirus as an anti-cancer therapy and hinge on the ongoing Phase III trial in head and neck cancer and other Phase II programmes.
URL
https://repository.icr.ac.uk/handle/internal/1737
Collections
  • Cancer Biology
  • Radiotherapy and Imaging
Version of record
10.1517/14712598.2012.745507
Subject
Humans
Head and Neck Neoplasms
Oncolytic Virotherapy
Mammalian orthoreovirus 3
Clinical Trials as Topic
Research team
Targeted Therapy
Language
eng
License start date
2012-12
Citation
Expert opinion on biological therapy, 2012, 12 (12), pp. 1669 - 1678

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.